会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • GLP-1 DERIVATIVES
    • GLP-1衍生物
    • WO2013037690A1
    • 2013-03-21
    • PCT/EP2012/067364
    • 2012-09-06
    • NOVO NORDISK A/SLAU, JesperBLOCH, PawKOFOED, JacobGARIBAY, Patrick
    • LAU, JesperBLOCH, PawKOFOED, JacobGARIBAY, Patrick
    • C07K14/605A61K38/26
    • C07K14/605A61K38/00A61K38/26
    • The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC-(CH 2 ) x -CO-*, and Chem. 16: HOOC-C 6 H 4 -O-(CH 2 ) y -CO-*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *-NH-CH(CH 2 OH)-CO-*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.
    • 本发明涉及GLP-1肽的衍生物,该肽与GLP-1(7-37)(SEQ)相比具有两个Lys残基,即第一和第二Lys残基,最多八个氨基酸变化 SEQ ID NO:3),该衍生物分别包含通过接头分别连接到所述第一和第二Lys残基的ε氨基的两个伸长部分,其中伸长部分选自Chem。 15:HOOC-(CH 2)x -CO- *,和Chem。 16:HOOC-C 6 H 4 -O-(CH 2)y -CO- *,其中x是10-16的整数,y是8-12的整数; 并且连接体包含第一连接体元件* -NH-CH(CH 2 OH)-CO- *。 优选的接头是g Glu-Ser-Ser-Gly-Ser-Ser-Gly(SEQ ID NO:2)。 本发明的衍生物具有非常好的效力,并且与GLP-1受体具有非常好的结合。 本发明还涉及衍生物的药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病。
    • 3. 发明申请
    • DOUBLE-ACYLATED GLP-1 DERIVATIVES
    • 双取代的GLP-1衍生物
    • WO2012140117A1
    • 2012-10-18
    • PCT/EP2012/056642
    • 2012-04-12
    • NOVO NORDISK A/SWIECZOREK, BirgitSPETZLER, JaneKRUSE, ThomasLINDEROTH, LarsKOFOED, Jacob
    • WIECZOREK, BirgitSPETZLER, JaneKRUSE, ThomasLINDEROTH, LarsKOFOED, Jacob
    • A01N43/90A01N61/00A01P3/00A61K38/26C07K14/065
    • C07K14/605A61K38/00A61K38/26A61K47/542A61K47/60
    • The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1 ); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K 27 , and the second K residue is designated K T ; which derivative comprises two albumin binding moieties attached to K 27 and K T , respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC-(CH 2 ) x -CO- and HOOC-C 6 H 4 -0-(CH 2 ) y -CO-; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula -NH-(CH 2 ) 2 -(O-(CH 2 ) 2 ) k -O-(CH 2 ) n -CO-, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.
    • 本发明涉及GLP-1类似物的衍生物,其类似物包含在对应于GLP-1(7-37)(SEQ ID NO:1)的位置27的位置处的第一个K残基; 在对应于GLP-1(7-37)的位置T的位置处的第二个K残基,其中T是除了18和27之外的7-37范围内的整数; 与GLP-1(7-37)相比最多10个氨基酸变化; 其中第一K残基指定为K27,第二K残基指定为KT; 该衍生物通过接头分别包含与K27和KT连接的两个白蛋白结合部分,其中白蛋白结合部分包含选自HOOC-(CH 2)x -CO-和HOOC-C 6 H 4 O-(CH 2)y -CO-; 其中x是6-16的整数,y是3-17的整数; 其中所述接头包含式-NH-(CH 2)2 - (O-(CH 2)2)kO-(CH 2)n -CO-的元素,其中k是1-5的整数,n 是1-5的整数; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型GLP-1类似物。 该衍生物适用于口服给药。
    • 4. 发明申请
    • DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER
    • 具有连接子的双取代的GLP-1衍生物
    • WO2012062804A1
    • 2012-05-18
    • PCT/EP2011/069743
    • 2011-11-09
    • NOVO NORDISK A/SKOFOED, JacobLAU, JesperLINDEROTH, LarsGARIBAY, Patrick WilliamKRUSE, Thomas
    • KOFOED, JacobLAU, JesperLINDEROTH, LarsGARIBAY, Patrick WilliamKRUSE, Thomas
    • A61K47/48A61P3/10
    • C07K14/605A61K47/542
    • The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1 : HOOC-(CH 2 ) x -CO-*, and Chem. 2: HOOC-C 6 H 4 -0-(CH 2 ) y -CO-*, in which x is an integer in the range of 6-18, and y is an integer in the range of 3-17; and the linker comprises Chem. 3: *-NH-(CH 2 ) q -CH[(CH 2 ) w -NH 2 ]-CO-*, wherein q is an integer in the range of 0-5, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are potent, protracted, and suitable for oral administration.
    • 本发明涉及GLP-1类似物的衍生物,其类似物在对应于GLP-1(7-37)(SEQ ID NO:1)的位置18的位置处的第一个K残基,另一个的第二个K残基 位置和与GLP-1(7-37)相比最多12个氨基酸变化; 该衍生物分别包含通过接头分别连接到所述第一和第二K残基的两个伸长部分,其中伸长部分选自Chem。 1:HOOC-(CH 2)x-CO- *,和Chem。 2:HOOC-C6H4-0-(CH2)y-CO- *,其中x是6-18的整数,y是3-17的整数; 连接体包括Chem。 3:* -NH-(CH 2)q-CH [(CH 2)w -NH 2] -CO- *,其中q是0-5的整数,w是0-5的整数 ; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型肽和侧链中间体。 衍生物有效,延长,适合口服。
    • 10. 发明申请
    • DOUBLE-ACYLATED GLP-1 DERIVATIVES
    • 双取代的GLP-1衍生物
    • WO2012062803A1
    • 2012-05-18
    • PCT/EP2011/069738
    • 2011-11-09
    • NOVO NORDISK A/SMADSEN, Alice RavnWIECZOREK, BirgitKOFOED, JacobLAU, JesperSPETZLER, JaneKODRA, János TiborLINDEROTH, LarsGARIBAY, Patrick WilliamSAUERBERG, PerKRUSE, Thomas
    • MADSEN, Alice RavnWIECZOREK, BirgitKOFOED, JacobLAU, JesperSPETZLER, JaneKODRA, János TiborLINDEROTH, LarsGARIBAY, Patrick WilliamSAUERBERG, PerKRUSE, Thomas
    • A61K47/48C07K14/605A61P3/10
    • C07K14/605A61K47/542
    • The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1 ), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem. : HOOC-(CH 2 ) x -CO-* Chem. 2: HOOC-C 6 H 4 -0-(CH 2 ) y -CO-* Chem. 3: R 2 -C 6 H 4 -(CH 2 ) z -CO-*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1 -5, and R 2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *-NH-(CH 2 ) 2 -(0-(CH 2 ) 2 ) k -0-(CH 2 ) n -CO-*. wherein k is an integer in the range of 1 -5, and n is an integer in the range of 1 -5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.
    • 本发明涉及GLP-1类似物的衍生物,其类似物包含在对应于GLP-1(7-37)(SEQ ID NO:1)的第18位的位置处的第一个K残基,另一个的第二个K残基 位置和与GLP-1(7-37)相比最多12个氨基酸变化; 该衍生物分别包含通过接头分别连接到所述第一和第二K残基的两个伸长部分,其中伸长部分选自Chem。 1,Chem。 2和Chem。 3:Chem。 :HOOC-(CH2)x-CO- * Chem。 2:HOOC-C6H4-0-(CH2)y-CO- * Chem。 3:R2-C6H4-(CH2)z-CO- *,其中x是6-18的整数,y是3-17的整数,z是1的整数 -5和R2是摩尔质量不高于150Da的基团; 连接体包括Chem。 4:* -NH-(CH 2)2 - (O-(CH 2)2)k -O-(CH 2)n -CO- *。 其中k是1-5的整数,n是1-5的整数; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药物用途,例如用于治疗和/或预防所有形式的糖尿病和相关疾病,以及相应的新型肽和侧链中间体。 该衍生物适用于口服给药。